Fulgent Genetics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
September 04 2020 - 8:00AM
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the
“company”), a technology company providing comprehensive testing
solutions through its scalable technology platform, today announced
that its Chairman and Chief Executive Officer Ming Hsieh, Chief
Financial Officer Paul Kim, and Chief Commercial Officer Brandon
Perthuis are scheduled to virtually participate in the H.C.
Wainwright 22nd Annual Global Investment Conference on Monday,
September 14, 2020. These representatives of the company will host
a presentation beginning at 1:00 p.m. ET.
A live webcast of the presentation will be
available on the Investor Relations section of the Fulgent Genetics
website at ir.fulgentgenetics.com. A replay of the webcast
will be accessible on the Events section of the IR website
beginning approximately one hour following the completion of the
event.
About Fulgent Genetics
Fulgent Genetics’ proprietary technology platform has created a
broad, flexible test menu and the ability to continually expand and
improve its proprietary genetic reference library while maintaining
accessible pricing, high accuracy and competitive turnaround times.
Combining next generation sequencing (“NGS”) with its technology
platform, the Company performs full-gene sequencing with
deletion/duplication analysis in an array of panels that can be
tailored to meet specific customer needs. In 2019, the Company
launched its first patient-initiated product, Picture Genetics, a
new line of at-home screening tests that combines the Company’s
advanced NGS solutions with actionable results and genetic
counseling options for individuals. Since March 2020, the Company
has commercially launched several tests for the detection of
SARS-CoV-2, the virus that causes the novel coronavirus
(“COVID-19”), including NGS and reverse transcription polymerase
chain reaction (“RT-PCR”) - based tests. The Company has received
Emergency Use Authorization (“EUA”) from the U.S. Food and Drug
Administration (“FDA”) for the RT-PCR-based tests for the detection
of SARS-CoV-2 using upper respiratory specimens (nasal,
nasopharyngeal, and oropharyngeal swabs) and for the at-home
testing service through Picture Genetics. A cornerstone of the
Company’s business is its ability to provide expansive options and
flexibility for all clients’ unique testing needs through a
comprehensive technology offering including cloud computing,
pipeline services, record management, web portal services, clinical
workflow, sequencing as a service and automated lab services.
About Picture Genetics
Through its Picture Genetics platform launched in 2019, Fulgent
Genetics offers consumers direct access to its advanced genetic
testing and analytics capabilities from the ease and comfort of
home, at an affordable price point. The Picture Genetics platform
provides a holistic approach to at-home genetic screening by
including oversight from independent physicians as well as genetic
counseling options to complement Fulgent Genetics’ comprehensive
genetic testing analysis. The Picture Genetics platform currently
offers multiple tests, providing medically actionable,
clinical-level results with professional medical follow-up in one
easy process. Visit www.picturegenetics.com for more
information.
Investor Relations Contact:The Blueshirt
GroupMelanie Solomon, 415-217-4964, melanie@blueshirtgroup.com
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Apr 2023 to Apr 2024